EP Patent

EP3274332B1 — Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride

Assigned to Sandoz AG · Expires 2018-12-19 · 7y expired

What this patent protects

Patent listed against amifampridine-phosphate.

Drugs covered by this patent

amifampridine-phosphate (AMIFAMPRIDINE PHOSPHATE)

Patent Metadata

Patent number: EP3274332B1
Jurisdiction: EP
Classification: —
Expires: 2018-12-19
Drug substance claim: No
Drug product claim: No
Assignee: Sandoz AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.